Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018. While some therapies in development hold promise, most have less favorable efficacy, safety and tolerability and/or delivery features compared with bevacizumab/paclitaxel/carboplatin.

"The bevacizumab/paclitaxel/carboplatin regimen attains current and future gold-standard status based on its superior overall survival in patients with advanced non-small-cell lung cancer," stated Decision Resources Analyst Laila Siddique.

The new report entitled Advanced Non-Small-Cell Lung Cancer: Lack of Efficacious Therapies in Development Presents Opportunity for an Agent That Can Increase Overall Survival also finds that a drug's effect on overall survival is the attribute that most influences surveyed oncologists prescribing decisions in advanced non-small-cell lung cancer. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage over sales leader bevacizumab/paclitaxel/carboplatin on this attribute.

"Oncologists we surveyed are enthusiastic about the improvements seen in efficacy resulting from the addition of bevacizumab to chemotherapeutic agents," added Ms. Siddique. "This enthusiasm however, stems solely from the ability of the regimen to increase overall survival beyond that seen with chemotherapy doublets."

About the Report

Advanced Non-Small-Cell Lung Cancer: Lack of Efficacious Therapies in Development

Presents Opportunity for an Agent That Can Increase Overall Survival is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at .

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Christopher Comfort   Decision Resources, Inc.   781-296-2597 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort, Decision Resources, Inc., +1-781-296-2597,

The Multiple Myeloma Drug Market Will More Than Double From $2.1 Billion in 2008 to $5.3 Billion in 2018

View Now